Cardiovascular therapeutics
Compounds and compositions comprising a B-type natriuretic signal peptide fragment agent, and methods of use thereof, are provided for the treatment or prevention of cardiovascular diseases, disorders, and conditions.
1. A method of treating a subject having or at risk for developing a cardiovascular disorder, comprising increasing Type-B natriuretic signal peptide fragment activity in said subject by administering to the subject a composition comprising a substantially pure Type-B natriuretic signal peptide fragment, wherein the amino acid sequence of said Type-B natriuretic signal peptide fragment consists of an amino acid sequence selected from one of SEQ ID NOS: 1 to 9.
2. A method according to claim 1 , wherein the cardiovascular disorder is an acute coronary syndrome selected from the group consisting of ST-segment elevation myocardial infarction, non-ST-segment elevation myocardial infarction and unstable angina.
3. A method according to claim 1 , wherein the composition comprises about 0.01 to about 100 milligrams of said Type-B natriuretic signal peptide fragment.
4. A method according to claim 1 , wherein the subject is a mammal.
5. A method according to claim 1 , wherein the amino acid sequence of the Type-B natriuretic signal peptide fragment consists of LHLAFLGGRS (SEQ ID NO: 1).
6. A method according to claim 1 , wherein the subject is a human.
7. A method according to claim 6 , wherein the amino acid sequence of the Type-B natriuretic signal peptide fragment consists of LHLAFLGGRS (SEQ ID NO: 1).
8. A method of treating a subject having or at risk for developing an acute coronary syndrome, comprising administering to the subject a composition comprising a Type-B natriuretic signal peptide fragment, wherein the amino acid sequence of said Type-B natriuretic signal peptide fragment consists of an amino acid sequence selected from one of SEQ ID NOS: 1 to 9.
9. A method according to claim 8 , wherein the cardiovascular disorder is an acute coronary syndrome selected from the group consisting of ST-segment elevation myocardial infarction, non-ST-segment elevation myocardial infarction and unstable angina.
10. A method according to claim 8 , wherein the composition comprises about 0.01 to about 100 milligrams of said Type-B natriuretic signal peptide fragment.
11. A method according to claim 8 , wherein the amino acid sequence of the Type-B natriuretic signal peptide fragment consists of LHLAFLGGRS (SEQ ID NO: 1).
12. A method according to claim 8 , wherein the subject is a mammal.
13. A method according to claim 12 , wherein the subject is a human.
14. A method according to claim 13 , wherein the amino acid sequence of the Type-B natriuretic signal peptide fragment consists of LHLAFLGGRS (SEQ ID NO: 1).